KRTX Karuna Therapeutics Inc

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the following upcoming investor conferences...

Rice Hall James Associates LLC purchased a new position in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor ...

Karuna Therapeutics, Inc. (NASDAQ:KRTX Get Free Report) has received an average rating of Moderate Buy from the twelve ratings firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The ...

Karuna Therapeutics, Inc. (NASDAQ:KRTX Get Free Report) CFO Troy A. Ignelzi sold 1,500 shares of the companys stock in a transaction dated Tuesday, August 22nd. The shares were sold at...

Ameritas Investment Partners Inc. grew its position in Karuna Therapeutics, Inc. (NASDAQ:KRTX Free Report) by 8.0% during the 1st quarter, HoldingsChannel.com reports. The firm owned 2,558...

Karuna Therapeutics (NASDAQ:KRTX Get Free Report)s stock had its neutral rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $214.00 target price on the stock. Cantor ...